what are Analysts report about Univar Inc.(NYSE:UNVR): Agile Therapeutics, Inc.(NASDAQ:AGRX)

0
4

Univar Inc. (UNVR) will report its next earnings on May 10 BMO. The company reported the earnings of $0.33/Share in the last quarter where the estimated EPS by analysts was $0.32/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 3.1%.

Many analysts are providing their Estimated Earnings analysis for Univar Inc. and for the current quarter 8 analysts have projected that the stock could give an Average Earnings estimate of $0.23/share. These analysts have also projected a Low Estimate of $0.11/share and a High Estimate of $0.33/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Univar Inc. as 2.25 Billion. According to these analysts, the Low Revenue Estimate for Univar Inc. is 2.11 Billion and the High Revenue Estimate is 2.37 Billion. The company had Year Ago Sales of 2.16 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for UNVR to be -45.2%. They are projecting Next Quarter growth of -6.38%. For the next 5 years, Univar Inc. is expecting Growth of 25.34% per annum, whereas in the past 5 years the growth was -8.64% per annum.

Some buy side analysts are also providing their Analysis on Univar Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Univar Inc. might touch $31 high while the Average Price Target and Low price Target is $27.5 and $26 respectively.

Univar Inc. closed its last trading session at $22.2 with the gain of 1.58%. The Market Capitalization of the company stands at 3.78 Billion. The Company has 52-week high of $31.23 and 52-week low of $16.33. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.38% where SMA50 and SMA200 are 0.51% and -6.65% respectively. The Company Touched its 52-Week High on 10/03/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.63 and Average Volume (3 months) is 1.73 million. The company’s P/E (price to earnings) ratio is 17.29 and Forward P/E ratio of 12.14.

The company shows its Return on Assets (ROA) value of 3.1%. The Return on Equity (ROE) value stands at 14.5%. While it’s Return on Investment (ROI) value is 9.8%.

While looking at the Stock’s Performance, Univar Inc. currently shows a Weekly Performance of -0.66%, where Monthly Performance is -1.01%, Quarterly performance is 14.7%, 6 Months performance is -19.81% and yearly performance percentage is -20.57%. Year to Date performance value (YTD perf) value is 27.11%. The Stock currently has a Weekly Volatility of 1.71% and Monthly Volatility of 2.41%.

Agile Therapeutics, Inc. (AGRX) will report its next earnings on Mar 18 AMC. The company reported the earnings of $-0.11/Share in the last quarter where the estimated EPS by analysts was $-0.15/share. The difference between the expected and actual EPS was $0.04/share, which represents an Earnings surprise of 26.7%.

Many analysts are providing their Estimated Earnings analysis for Agile Therapeutics, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.1/share. These analysts have also projected a Low Estimate of $-0.11/share and a High Estimate of $-0.09/share.

These analysts also forecasted Growth Estimates for the Current Quarter for AGRX to be 47.6%. They are projecting Next Quarter growth of 37.5%. For the next 5 years, Agile Therapeutics, Inc. is expecting Growth of 0.73% per annum, whereas in the past 5 years the growth was 20.69% per annum.

Some buy side analysts are also providing their Analysis on Agile Therapeutics, Inc., where 3 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Agile Therapeutics, Inc. might touch $4 high while the Average Price Target and Low price Target is $3.5 and $3 respectively.

Agile Therapeutics, Inc. closed its last trading session at $1.48 with the loss of -0.68%. The Market Capitalization of the company stands at 62.3 Million. The Company has 52-week high of $3.00 and 52-week low of $0.23. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.35% where SMA50 and SMA200 are 18.79% and 94.08% respectively. The Company Touched its 52-Week High on 04/24/18 and 52-Week Low on 08/13/18.

The Relative Volume of the company is 0.5 and Average Volume (3 months) is 570.01 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -59.3%. The Return on Equity (ROE) value stands at -78.9%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Agile Therapeutics, Inc. currently shows a Weekly Performance of -2.65%, where Monthly Performance is -9.26%, Quarterly performance is 88.41%, 6 Months performance is 124.15% and yearly performance percentage is -49.66%. Year to Date performance value (YTD perf) value is 155.25%. The Stock currently has a Weekly Volatility of 7.21% and Monthly Volatility of 5.53%.

SHARE